Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...

The research on glioblastoma requires the development of new preclinical murine models. The GL261 cell line forms glioma-like tumors in a reliable manner when transplanted intracranially, but these ...

Earlier asunercept glioblastoma multiforme (GBM) clinical trial data showed favorable safety and tolerability, prolonged survival and improved quality-of-life. Asunercept has been granted US FDA ...

Window of opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent ...

USC has received a $6m grant from the California Institute for Regenerative Medicine (CIRM) to advance a new gene therapy for ...

That was on Nov. 25. This time, Chen, as part of a clinical trial at Rhode Island Hospital used a radiation treatment, on the ...

In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, discusses what she is most looking forward to in the future of brain ...

Glioblastoma (GBM), an aggressive form of cancer that grows in the brain or spinal cord, occurs at an incidence rate of about 3/100,000 persons in the Unit | Cancer ...

"Imvax secures $29m to support Phase IIb glioblastoma therapy trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been ...

MimiVax, Inc., a leader in clinical-stage pharmaceutical research, today announced that its now fully enrolled Phase 2b clinical trial of SurVaxM in glioblastoma, [SURVIVE] (NCT05163080), has ...

today announced that its now fully enrolled Phase 2b clinical trial of SurVaxM in glioblastoma, [SURVIVE] (NCT05163080), has successfully progressed following the first interim analysis of trial data.